Johnson & Johnson (JNJ) will provide additional supply of its cancer drug Doxil for use in clinical trials, including one testing whether the combination of an experimental Endocyte Inc. drug vintafolide (EC-145) with Doxil improves treatment of ovarian cancer.
- Libby's H*O*P*E*